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schemic stroke is caused by an obstruction of ce-
rebral blood flow, often due to a blood clot or 
severe atherosclerotic plaque with ulceration or 
plaque rupture. An important part of treatment and preven-
tion of ischemic stroke is the use of antithrombotic agents. 
Patient medical history, health status, etiology of stroke, 
vascular imaging appearance, and stroke burden determine 
which antithrombotic therapies are used. After an initial 
stroke, preventing a second stroke is the main focus. In many 
cases, the risk of recurrent stroke can be reduced through 
lifestyle modifi cations and medications.
Antithrombotic medications, such as aspirin, clopido-
grel, and warfarin, are important strategies in stroke preven-
tion, and adherence to antithrombotics reduces the risk of 
recurrent stroke.1 New target-specifi c antithrombotics add 
complexity to the armamentarium of antithrombotic ther-
apy in stroke. This article provides an overview of anti-
thrombotics in ischemic stroke for the primary care nurse 
practitioner (PCNP). The evidence for best practices for 
antithrombotic use in stroke is reviewed, along with a dis-
cussion of the specifi c agents and their use in managing and 
preventing ischemic stroke.
■ Background
Throughout the 14th to 19th centuries, apoplexy was de-
scribed as the sudden loss of consciousness followed by 
sudden death (what is now referred to as stroke).2 Today, 
ischemic stroke is defi ned as pathologic, imaging, or clinical 
evidence of cerebral, spinal, or retinal focal ischemic injury 
in a defi ned vascular distribution.3 The term stroke illness 
was fi rst used in 1962 by the Chest and Heart Association, 
and the term stroke continues to be used today to describe 
this serious global disease that affects 15 million individuals 
worldwide and 6.6 million individuals throughout the Unit-
ed States.4
Someone has a stroke every 40 seconds in the United 
States, making it a leading cause of death.4 There are 6.4 
million stroke survivors in the United States, and stroke is 
the leading cause of long-term disability. Stroke has a 2.6% 
nationwide prevalence and a projected 20.5%  increased 
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Abstract: The use of antithrombotic medications is an important component of 
ischemic stroke treatment and prevention. This article reviews the evidence for 
best practices for antithrombotic use in stroke with focused discussion on 
the specifi c agents used to treat and prevent stroke. 
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prevalence, equaling a 3.12% national increase by 2030.4 
Stroke disproportionately affects vulnerable, ethnic, and 
underserved populations due to the high prevalence of 
vascular risk factors, which lead to higher stroke risk.
Strokes are classifi ed as ischemic or hemorrhagic and may 
occur in the arterial or venous system. Arterial ischemic strokes 
occur mainly in the setting of thrombus formation, emboli, 
or critical stenosis, causing an occlusion or hemodynamically 
signifi cant obstruction of blood fl ow to the brain.5 Dramatic 
improvement in understanding stroke has been gained from 
advanced central nervous system medical imaging and re-
searching the nature of ischemia and cerebral infarction.
Stroke systems of care utilize an organized team ap-
proach to decrease hospital stay and mortality for acute 
stroke patients admitted to a dedicated stroke unit. This has 
led to advanced treatments for stroke and the development 
of team-based care for delivery and management.6
As stroke patients transition across the healthcare con-
tinuum, many return home. Most stroke patients will need 
antithrombotics continued after discharge, and often, this 
responsibility is returned to the primary care provider. Pre-
scribed medication nonadherence is considered a universal 
cardiovascular risk factor.7 Nonadherence to antithrom-
botic secondary prevention strategies in ischemic stroke 
results from a variety of factors, including adverse reactions, 
cost, inability to travel to their provider or local pharmacy, 
or discontinuation by the patient or primary care provider.
Nonadherence disrupts the effectiveness of therapy and 
directly increases risk of subsequent stroke.1 Improved com-
munication and collaboration are necessary to enhance 
stroke patient transitions.6 Stroke team specialists should 
communicate directly with the PCNP related to continuing 
antithrombotic therapies. Best-practice evidence related to 
adherence to antithrombotics and the relationship to de-
creasing stroke or recurrent stroke risk should be shared 
with the PCNP.
Additionally, the stroke team should openly communi-
cate with PCNPs and ensure antithrombotic treatments 
begun in the hospital are continued. PCNPs can participate 
by contacting stroke team specialists to determine which 
antithrombotic medications were prescribed should there 
be a communication delay from the stroke team specialist 
to the PCNP.
■ Initial stroke treatment with fi brinolytics
Since 1995, tissue plasminogen activator (tPA), which is 
produced by recombinant DNA technology, has been cen-
tral to treating acute ischemic stroke, and it remains the 
only FDA-approved drug treatment for acute ischemic 
stroke. Initial clinical trials demonstrated benefi ts of I.V. 
fi brinolysis in patients with acute ischemic stroke treated 
within 3 hours of symptom onset, and subsequent studies 
have extended that time window to 4.5 hours in selected 
patients (although use of tPA beyond 3 hours from stroke 
onset remains off-label use).8,9 Intra-arterial fi brinolysis 
and mechanical thrombectomy are also treatment options 
for acute ischemic stroke.
The tPA alteplase is the only FDA- approved fibrino-
lytic agent used in acute ischemic stroke. It is a natural 
enzyme that initiates local fibrinolysis by binding to fi-
brin within a clot while also directly activating plas-
minogen to promote further fibrinolysis. It can be ad-
ministered I.V. or intra-arterially. Alteplase is the drug of 
choice for reperfusion in acute ischemic stroke and im-
proves stroke outcomes by 30%. I.V. doses are based upon 
weight up to a maximum total of 90 mg. Intracranial 
hemorrhage must be excluded prior to administration. 
Other exclusion criteria include, but are not limited to: 
BP greater than 185/110; international normalized ratio 
(INR) greater than 1.7; prothrombin 
time (PT) greater than 15 seconds; 
and platelets less than 100,000/mm3.8,9
Evaluation of the data from five 
stent retriever stroke trials (MR CLEAN, 
ESCAPE, SWIFT-PRIME, EXTEND-IA 
and REVASCAT) resulted in new rec-
ommendations in the 2015 American 
Heart Association/American Stroke Association Focused 
Update of the 2013 Guidelines for the Early Management 
of Patients With Acute Ischemic Stroke Regarding Endovas-
cular Treatment. Class IA evidence changes include treating 
patients who meet appropriate criteria with stent retrievers; 
performing non-invasive vascular imaging as part of the initial 
imaging  assessment of stroke as long as it does not delay deliv-
ery of I.V. tPA. The updated guidelines are available at 
http://stroke.ahajournals.org/content/early/2015/06/26/ 
R.0000000000000074.
■ Antithrombotics in stroke
Antithrombotic agents (medications that inhibit platelet 
function or affect the coagulation pathway to inhibit throm-
bus propagation or activate thrombolysis) represent an 
 integral component of ischemic stroke management and 
prevention. Acute ischemic stroke treatment has been rev-
olutionized by two major therapeutic advancements in the 
Stroke systems of care utilize an organized 
team approach to decrease hospital stay and 
mortality for acute stroke patients.
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last 20 years: thrombolytic therapy and mechanical throm-
bectomy.
Antiplatelet agents provide benefi ts in acute ischemic 
stroke treatment. Randomized control trials have demon-
strated that early administration of aspirin (160 mg or 325 
mg) results in a mild reduction in mortality and improve-
ment in functional outcome when administered within 24 
to 48 hours of symptom onset.10 Earlier administration of 
aspirin carries a small risk of hemorrhage. Early general 
administration of anticoagulants for 
arterial ischemic stroke has also been 
evaluated, demonstrating an increase 
in mortality and unfavorable clinical 
outcomes compared with placebo or 
aspirin.11 As a complication of stroke, 
deep venous thromboembolic disease 
remains an important consideration 
in patients immobilized with acute ischemic stroke. These 
patients benefi t from subcutaneous heparin or low-mo-
lecular-weight heparin prophylactic dose anticoagulation 
and/or mechanical thromboprophylaxis.
Antiplatelets and anticoagulants are important in both 
primary and secondary stroke prevention. In patients with 
noncardioembolic ischemic stroke, antiplatelet agents play 
a secondary and somewhat debatable role in primary stroke 
prevention, behind modifi able risk factors, including ap-
propriate diet; adequate exercise; and BP, glycemic, and 
cholesterol management. An individualized approach is 
advocated for antiplatelet agents for primary stroke preven-
tion, and aspirin is often recommended in patients with 
clinical atherosclerotic disease, elevated cholesterol, obesity, 
and lifestyle risk factors that increase stroke risk.12
In secondary prevention of noncardioembolic ischemic 
stroke, the data are clear that antiplatelet agents demonstrate 
decreased mortality, a reduction in recurrent strokes, and 
reduction in myocardial infarction (with a slight increase in 
major extracranial hemorrhage). The majority of clinical 
evidence comes from evaluating adult-dose aspirin (325 mg), 
although newer antiplatelet agents have also been evaluated.
The choice of antiplatelet agent remains somewhat 
controversial, with studies suggesting slightly improved 
patient outcomes with clopidogrel or aspirin/extended-
release dipyridamole over aspirin alone. The use of a dual 
antiplatelet regimen appears to produce no significant 
clinical benefi t over monotherapy, at the cost of an increased 
risk of symptomatic hemorrhage.13 The use of oral antico-
agulation also appears to produce no signifi cant clinical 
benefi t over antiplatelet treatment and noncardioembolic 
stroke, with an increased risk of symptomatic hemorrhage.13
The majority of cardioembolic ischemic strokes arise 
from cardiac dysrhythmias (most commonly atrial fi brillation 
[AF]). AF is known to increase the risk of ischemic stroke as 
much as fi vefold; primary stroke prevention in this population 
involves oral anticoagulation.14 A number of newer antico-
agulants now complement warfarin, and treatment regimens 
can be tailored to account for  variability in the risk-benefi t 
ratio for individual patients. Scoring systems such as the 
CHA2DS2-VAS
C
 allow for individual risk stratifi cation.15
Secondary stroke prevention may involve anticoagulant or 
antiplatelet therapy. As with primary prevention, formulating 
an appropriate management plan in this patient population is 
complex, with multiple variables to consider, including:
• patient preference
• risk of complications or other drug interactions
• age
• comorbidities (such as kidney dysfunction)
• ability to afford medication
• ability to maintain therapeutic INR range.
Oral anticoagulation is the treatment of choice for sec-
ondary stroke prevention in the setting of AF in patients 
with no major contraindication to anticoagulation therapy.
Ideally, anticoagulation should begin within 2 weeks of 
stroke onset, although the risk of hemorrhage related to 
early anticoagulation in patients with large strokes is high-
er, often times necessitating delayed initiation. Antiplatelet 
agents have demonstrated reduction of recurrent strokes in 
patients with AF who have a contraindication for oral anti-
coagulation as secondary stroke prevention. Dual antiplate-
let therapies appear to be more effective than monotherapy 
in this patient population.13
■ Heparin
Unfractionated heparin (heparin). Heparin is used in acute 
stroke during mechanical thrombectomy, when administer-
ing intrarterial alteplase, and in presence of a large, intralu-
minal thrombotic or embolic fi lling defect of the major ce-
rebral arteries.16 Heparin inhibits clot formation by binding 
to antithrombin III, converting it from a slow inhibitor to a 
very rapid inhibitor. This interaction leads to overall inhibi-
tion of procoagulant activity by inactivating thrombin as 
well as activated factors IX, X, XI, XII, and plasmin; therefore, 
it inhibits further growth and propagation of a thrombus.
Heparin can be administered I.V. or subcutaneously. 
I.V. infusion is the recommended route of administration 
Early administration of aspirin results in 
a mild reduction in mortality when given 
within 24 to 48 hours of symptom onset.
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due to consistent outcomes. Subcutaneous dosing needs to 
be higher due to decreased bioavailability, and dosing is 
based on weight. Heparin can be reversed with protamine. 
Bleeding complications appear to be dose dependent. 
Achieving therapeutic activated partial thromboplastin 
time (APTT) values is the treatment goal by tailoring a dose 
to each individual. A number of weight-based and dose 
titration nomograms are available as guidelines. The rela-
tive short half-life (0.4 to 2.5 hours) of heparin enables 
achievement of therapeutic values quickly while also pro-
viding the fl exibility to withhold anticoagulation as neces-
sary (preprocedural).16,17
Low-molecular-weight heparin (LMWH). LMWHs po-
tentiate antithrombin III activity to inhibit thrombus forma-
tion and are used as a bridge when converting to or from 
oral anticoagulants, although equivalent anticoagulant 
agents can be used if the patient is intolerant to heparin. Due 
to their smaller size, LMWHs promote specifi c factor Xa 
inactivation and just a small amount of thrombin inactiva-
tion when compared with heparin. Each LMWH is derived 
slightly differently from one another, giving each medication 
a unique pharmacokinetic profi le and dosing regimen.
LMWHs are most commonly given subcutaneously but 
can also be administered I.V. They are an excellent choice for 
outpatient use and when a bridging anticoagulant is necessary 
(for example, while initiating warfarin therapy). Therapeutic 
levels can be reached relatively easily and reliably due to excel-
lent bioavailability and little interpatient variability. Dose 
adjustments might be necessary in patients with decreased 
kidney function and for those who are morbidly obese.
Although routine monitoring is not considered nec-
essary, antifactor Xa levels can be useful to confirm 
 therapeutic levels, although it does not help in determining 
the reversal’s effect. There is currently no documented re-
versal for LMWH. Protamine can be used to reverse bleed-
ing in some patients using LMWH, but it only partially 
affects anti-Xa levels. Cross-reactivity with LMWH is pos-
sible in a patient with previously documented heparin-
induced thrombocytopenia.16
■ Oral anticoagulants
Warfarin. The most common vitamin K antagonist, 
 warfarin is used to prevent stroke in AF and other 
 cardioembolic conditions; it imparts a 70% relative risk 
reduction. The antithrombotic effect of warfarin is attrib-
uted to its anticoagulant effect and interferes with the he-
patic synthesis of the vitamin K-dependent coagulation 
factors II (prothrombin), VII, IX, and X, and proteins C 
and S. It takes approximately 5 to 6 days for full antithrom-
botic effect to take place. This is due to the relatively long 
half-life (60 to 72 hours) of factor II compared with 
the  other vitamin K-dependent coagulation factors (6 to 
24 hours).
The time it takes to lower factor II levels is the basis for 
overlapping a parenteral anticoagulant with warfarin for 
approximately 5 days. Known genetic polymorphisms, 
drug-drug interactions, nutritional supplements, and herb-
al products can affect therapeutic outcomes. Additionally, 
a narrow therapeutic index combined with interpatient 
variability can make determining an appropriate dose for 
each patient challenging. PT/INR values are commonly used 
to monitor therapy. Withholding doses, administration of 
phytonadione, and administration of blood derivatives such 
as fresh frozen plasma are all strategies for reversal. The 
reversal choice depends upon how urgently the patient 
needs reversal.18-20
Dabigatran. This direct oral anticoagulant is an alter-
native to the common disadvantages of warfarin. It is FDA 
approved for stroke prevention in nonvalvular AF. Dabi-
gatran is a direct thrombin inhibitor, which is currently 
available in an oral formulation and does not require a 
cofactor to inhibit thrombin. Unlike warfarin, doses are 
fi xed and based on kidney function. Dose adjustments are 
recommended based on kidney func-
tion, and dabigatran should be avoid-
ed in severe kidney failure. Both PT 
and APTT are unchanged with treat-
ment. Proton pump inhibitors often 
used for gastroesophageal refl ux dis-
ease or gastrointestinal acid refl ux may 
decrease its absorption, and coadmin-
istration should be avoided.
Coadministration with strong  P-glycoprotein inhibitors 
(ketoconazole, amiodarone) or inducers  (rifampicin) may 
signifi cantly increase or decrease dabigatran levels, respec-
tively, and should be avoided. Depending upon kidney func-
tion, doses need to be held anywhere from 1 to 4 days prior 
to any invasive procedure. The monoclonal antibody frag-
ment idarucizumab is a recently FDA approved (October 
2015) antidote that fi rmly binds to dabigatran reversing the 
anticoagulant effects. Discontinuing dabigatran followed by 
volume and red blood cell replacement (or hemodialysis) is 
also recommended for clinical management of any major 
bleeding.18,21
The most common vitamin K antagonist, 
warfarin is used to prevent stroke in AF 
and other cardioembolic conditions.
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Apixaban, a factor Xa inhibitor, is more 
effective than warfarin in prevention of 
strokes in nonvalvular AF.
Rivaroxaban. This direct oral anticoagulant is a direct 
factor Xa inhibitor. It is available in an oral formulation 
dosed once daily for all indications. Specifi c doses depend 
upon kidney function and indication. Avoid use in severe 
kidney impairment. Just as with dabigatran, coadministra-
tion with strong P-glycoprotein  inhibitors or inducers 
should be avoided. Additionally, concomitant use of strong 
inhibitors of both CYP3A4 and P-glycoprotein (ketocon-
azole, HIV protease inhibitors) is contraindicated due to 
increased levels of rivaroxaban. PT and APTT should not 
be used to monitor therapy. There is no reversal agent avail-
able at this time although reversal agents for rivaroxaban 
and apixaban are in clinical trials. There 
is risk of thromboembolic events due 
to a hypercoagulable state with prema-
ture discontinuation.18,21,22
Apixaban. This factor Xa inhibitor 
is more effective than warfarin in pre-
vention of strokes in nonvalvular AF.23 
The reduction of intracranial hemor-
rhage risk and overall mortality is an advantage of apixaban 
over warfarin, although there is no signifi cant risk reduc-
tion of cerebral embolism. Apixaban is dosed twice daily 
and dosing is adjusted in patients over age 80, weighing 
less than 60 kg, or having a creatinine level 1.5 mg/dL or 
greater; or when coadministered with drugs that are strong 
inhibitors of CYP3A and P-glycoprotein. Apixaban has a 
Black Box Warning regarding premature discontinuation 
that increases the risk of thromboembolic events without 
a replacement anticoagulant. No reversal agent is cur-
rently approved for apixaban, and routine blood monitor-
ing is not required.23
Edoxaban. This once-daily direct factor Xa inhibitor 
was approved for prevention of stroke in January 2015 in 
patients with stroke due to nonvalvular AF. It is contrain-
dicated in patients with a creatinine clearance greater than 
95 mL/minute, as this was shown to increase the risk of 
ischemic stroke when compared with warfarin. Edoxaban 
is given as a once-daily dose based on the creatinine clear-
ance level. It should not be used with creatinine clearance 
above 95 or below 14 mL/min.24
Kidney function should  be monitored when using 
edoxaban. Like other direct factor Xa inhibitors, bleeding 
is the most common adverse reaction, and infusion of 
blood coagulation factors are used as reversal agents as 
there is no specific reversal agent for edoxaban. Edoxaban 
requires a 50% dose reduction in patients under 60 kg, 
or in patients who use the P-glycoprotein inducer ri-
fampin or P-glycoprotein inhibitors. Serial coagulation 
monitoring is not indicated, but PT and aPTT may be 
altered.
■ Antiplatelets
Aspirin. Antiplatelets are used in stroke to decrease stroke 
risk and recurrence. Aspirin blocks prostaglandin synthesis, 
which prevents formation of the platelet-aggregating sub-
stance thromboxane A
2
. Antiplatelet effects can be attained 
at low doses due to their selective inhibition of COX-1. 
Aspirin is absorbed rapidly from the stomach and small 
intestine.
Enteric-coated or sustained-release formulations should 
be used cautiously due to lower bioavailability. Aspirin has 
been widely studied in both preventive and treatment set-
tings. Aspirin 160 mg to 325 mg daily should be initiated 
within 48 hours of onset of acute ischemic stroke in all 
patients after considering any possible contraindications. 
Continue treatment for approximately 1 to 2 weeks before 
initiating a long-term antiplatelet regimen.19,25,26
Dipyridamole. This oral pyridopyrimidine derivative has 
antiplatelet and vasodilatory properties. Extended-release 
dipyridamole is available as a combination product with 
aspirin and may be useful in secondary prevention in pa-
tients with a history of transient ischemic attack (TIA) or 
stroke.13 Although the mechanism of dipyridamole as an 
antiplatelet is controversial, increases in plasma adenosine 
and inhibition of cyclic nucleotide phosphodiesterase have 
been suggested. It should not be given to those with severe 
kidney or hepatic impairment or those with a known al-
lergy to nonsteroidal anti-infl ammatory drugs.26
■ Thienopyridines
Ticlopidine, clopidogrel, and prasugrel attain their antiplate-
let effects by irreversibly inhibiting adenosine diphosphate 
to bind to the P2Y
12
 receptor on platelets. All are prodrugs 
that must be activated via the hepatic CYP450 system.19,26
Ticlopidine. The current therapeutic role for ticlopidine 
is currently uncertain due to its association with hypercho-
lesterolemia, neutropenia, thrombocytopenia, aplastic ane-
mia, and thrombotic thrombocytopenic purpura.19,26
Clopidogrel. An oral P2Y
12
-receptor antagonist, clopido-
grel binds irreversibly to the P2Y
12
 site for the life of the 
platelet, inhibiting adenosine diphosphate-induced platelet 
aggregation. The degree of inhibition can vary between 
patients, causing an increase in thrombotic events in patients 
with clopidogrel resistance. Smoking can cause active 
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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 metabolite levels to vary. Medications that induce or in-
hibit CYP450 isoenzymes involved in converting clopidogrel 
to its active form, as well as genetic polymorphisms of 
CYP450, can cause variable active metabolite generation.
Of note, omeprazole and esomeprazole, both of which 
are substrates and inhibitors of CYP2C19, are associated 
with a decrease in effectiveness of clopidogrel. Pantopra-
zole offers an option with a lesser degree of interaction. 
Loading doses of clopidogrel provide more rapid platelet 
inhibition; onset of action is approximately 2 to 4 hours. 
Platelet function returns to normal 7 to 10 days after dis-
continuation.19,26
Prasugrel. This oral P2Y
12
-receptor
 
inhibitor is rapidly 
absorbed, reaching peak concentrations within 30 minutes. 
Absorption is unaffected by food. Currently, no evidence is 
available to show that genetic polymorphisms or use of 
proton pump inhibitors interfere with metabolism. Platelet 
function returns to normal 7 to 10 days after discontinua-
tion. Prasugrel carries an FDA Black Box Warning for sig-
nifi cant or sometimes fatal bleeding. Its use is contraindi-
cated in patients with active pathologic bleeding, TIA, or 
history of stroke.19,26
■ Cyclopentyl-triazolo-pyrimidines
Ticagrelor. This rapidly absorbed oral direct-acting P2Y12-
receptor antagonist binds reversibly and noncompetitively 
to the P2Y
12
 site. Unlike the thienopyridines, it is not a pro-
drug, so is not dependent on metabolism for activation. It 
provides low interindividual variability, and onset is about 
30 minutes. No dose adjustment in kidney impairment or 
mild hepatic impairment is considered necessary; however, 
avoid use in patients with moderate-to-severe hepatic im-
pairment. Coadministration with CYP3A4 inhibitors and 
inducers (simvastatin) as well as P-glycoprotein substrates 
(digoxin) should be used with caution.
Ticagrelor carries an FDA Black Box Warning stating 
that maintenance of daily doses of aspirin greater than 100 
mg should be avoided due to decreased effectiveness of ti-
cagrelor. There is no statistically signifi cant risk of bleeding 
with ticagrelor when compared with clopidogrel. Ticagrelor 
has been associated with dyspnea and an increase in ven-
tricular pauses (longer than 2.5 seconds, possibly due to its 
ability to delay adenosine metabolism).19,26,27
■ Moving forward
Antithrombotics are an integral part of ischemic stroke 
treatment, management, and prevention. Continuing an-
tithrombotics after discharge is an important strategy to 
decrease recurrent stroke risk. There is a complex algo-
rithm of radiographic and clinical assessments involved 
in the clinical decision-making that determines which 
antithrombotic therapy is recommended to the patient by 
the stroke team. Each anticoagulant and antiplatelet has 
advantages and disadvantages that may affect patient 
 adherence.
Recommendations should be communicated clearly to 
the patient by the stroke team and the PCNP for improved 
patient adherence. Additionally, the PCNP should be in-
cluded in the community of stroke team providers as they 
assist the patient in managing stroke risk factors after dis-
charge and can help the patient understand the importance 
of continuing their antithrombotics as part of a stroke risk 
reduction program. Improved communication between the 
stroke team and the PCNP can also lead to identifying meth-
ods and models of improved communication and collabo-
ration in stroke care. 
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